Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
Por:
Garcia-Delgado, R, de Miguel, D, Bailen, A, Gonzalez, JR, Bargay, J, Falantes, JF, Andreu, R, Fernando, R, Tormo, M, Brunet, S, Figueredo, A, Casano, J, Medina, A, Badiella, L, Jurado, AF, Sanz, G
Publicada:
1 jul 2014
Resumen:
We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. (C) 2014 The Authors. Published by Elsevier Ltd.
Filiaciones:
Garcia-Delgado, R:
Hosp Univ Virgen Victoria, Malaga, Spain
de Miguel, D:
Hosp Univ Guadalajara, Madrid, Spain
Bailen, A:
Hosp Carlos Haya, Malaga, Spain
Gonzalez, JR:
Hosp Clin Univ, Salamanca, Spain
Bargay, J:
Hosp Son Llatzer, Palma De Mallorca, Spain
Falantes, JF:
Hosp Univ Virgen Rocio, IBIS, Seville, Spain
Andreu, R:
Hosp Doctor Peset, Valencia, Spain
Fernando, R:
Hosp Gen Leon, Leon, Spain
Tormo, M:
Hosp Clin Univ Valencia, Valencia, Spain
Brunet, S:
Hosp Santa Creu I Sant Pau, Barcelona, Spain
Figueredo, A:
Hosp Virgen Macarena, Seville, Spain
Casano, J:
Hosp Reina Sofia, Cordoba, Spain
Medina, A:
Hosp Costa del Sol, Marbella, Spain
Badiella, L:
Univ Autonoma Barcelona, Serv Estadist Aplicada, E-08193 Barcelona, Spain
Jurado, AF:
Hosp Juan Ramon Jimenez, Huelva, Spain
Asociac Andaluza Hematol & Hemoterapia, Valencia, Spain
Sanz, G:
Hosp Univ La Fe, Valencia, Spain
Hybrid Gold
|